Spectrum and dosing of urate-lowering drugs in a large cohort of chronic kidney disease patients and their effect on serum urate levels: a cross-sectional analysis from the German Chronic Kidney Disease study

Kielstein JT, Heisterkamp M, Jing J, Nadal J, Schmid M, Kronenberg F, Busch M, Sommerer C, Lorenzen JM, Eckardt KU, Koettgen A (2021)


Publication Type: Journal article

Publication year: 2021

Journal

Book Volume: 14

Pages Range: 277-283

Journal Issue: 1

DOI: 10.1093/ckj/sfz136

Abstract

Background: Despite a plethora of studies on the effect of urate-lowering therapy (ULT) in patients with chronic kidney disease (CKD), current guidelines on the treatment of hyperuricaemia and gout vary, especially concerning the need for dose adjustment of allopurinol, whose main metabolite is accumulating with declining renal function. Data on allopurinol dosing and its relationship to renal function, co-medication and sex and the resulting urate level in large cohorts are missing.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Kielstein, J.T., Heisterkamp, M., Jing, J., Nadal, J., Schmid, M., Kronenberg, F.,... Koettgen, A. (2021). Spectrum and dosing of urate-lowering drugs in a large cohort of chronic kidney disease patients and their effect on serum urate levels: a cross-sectional analysis from the German Chronic Kidney Disease study. Clinical Kidney Journal, 14(1), 277-283. https://doi.org/10.1093/ckj/sfz136

MLA:

Kielstein, Jan T., et al. "Spectrum and dosing of urate-lowering drugs in a large cohort of chronic kidney disease patients and their effect on serum urate levels: a cross-sectional analysis from the German Chronic Kidney Disease study." Clinical Kidney Journal 14.1 (2021): 277-283.

BibTeX: Download